vs
AdvanSix Inc.（ASIX）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
Pediatrix Medical Group, Inc.的季度营收约是AdvanSix Inc.的1.4倍（$493.8M vs $359.9M），Pediatrix Medical Group, Inc.净利率更高（6.8% vs -0.8%，领先7.6%），AdvanSix Inc.同比增速更快（9.4% vs -1.7%），过去两年AdvanSix Inc.的营收复合增速更高（3.4% vs -0.1%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
ASIX vs MD — 直观对比
营收规模更大
MD
是对方的1.4倍
$359.9M
营收增速更快
ASIX
高出11.1%
-1.7%
净利率更高
MD
高出7.6%
-0.8%
两年增速更快
ASIX
近两年复合增速
-0.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $493.8M |
| 净利润 | $-2.8M | $33.7M |
| 毛利率 | 7.6% | — |
| 营业利润率 | -0.7% | 9.9% |
| 净利率 | -0.8% | 6.8% |
| 营收同比 | 9.4% | -1.7% |
| 净利润同比 | -892.9% | 10.5% |
| 每股收益（稀释后） | $-0.11 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXMD
| Q4 25 | $359.9M | $493.8M | ||
| Q3 25 | $374.5M | $492.9M | ||
| Q2 25 | $410.0M | $468.8M | ||
| Q1 25 | $377.8M | $458.4M | ||
| Q4 24 | $329.1M | $502.4M | ||
| Q3 24 | $398.2M | $511.2M | ||
| Q2 24 | $453.5M | $504.3M | ||
| Q1 24 | $336.8M | $495.1M |
净利润ASIXMD
| Q4 25 | $-2.8M | $33.7M | ||
| Q3 25 | $-2.6M | $71.7M | ||
| Q2 25 | $31.4M | $39.3M | ||
| Q1 25 | $23.3M | $20.7M | ||
| Q4 24 | $352.0K | $30.5M | ||
| Q3 24 | $22.3M | $19.4M | ||
| Q2 24 | $38.9M | $-153.0M | ||
| Q1 24 | $-17.4M | $4.0M |
毛利率ASIXMD
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
营业利润率ASIXMD
| Q4 25 | -0.7% | 9.9% | ||
| Q3 25 | -0.9% | 13.8% | ||
| Q2 25 | 7.7% | 12.8% | ||
| Q1 25 | 7.7% | 7.0% | ||
| Q4 24 | -3.9% | 7.8% | ||
| Q3 24 | 7.5% | 6.6% | ||
| Q2 24 | 11.5% | -31.3% | ||
| Q1 24 | -7.0% | 3.2% |
净利率ASIXMD
| Q4 25 | -0.8% | 6.8% | ||
| Q3 25 | -0.7% | 14.5% | ||
| Q2 25 | 7.7% | 8.4% | ||
| Q1 25 | 6.2% | 4.5% | ||
| Q4 24 | 0.1% | 6.1% | ||
| Q3 24 | 5.6% | 3.8% | ||
| Q2 24 | 8.6% | -30.3% | ||
| Q1 24 | -5.2% | 0.8% |
每股收益（稀释后）ASIXMD
| Q4 25 | $-0.11 | $0.40 | ||
| Q3 25 | $-0.10 | $0.84 | ||
| Q2 25 | $1.15 | $0.46 | ||
| Q1 25 | $0.86 | $0.24 | ||
| Q4 24 | $0.02 | $0.37 | ||
| Q3 24 | $0.82 | $0.23 | ||
| Q2 24 | $1.43 | $-1.84 | ||
| Q1 24 | $-0.65 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $375.2M |
| 总债务越低越好 | — | $570.5M |
| 股东权益账面价值 | $815.2M | $865.9M |
| 总资产 | $1.7B | $2.2B |
| 负债/权益比越低杠杆越低 | — | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资ASIXMD
| Q4 25 | $19.8M | $375.2M | ||
| Q3 25 | $23.7M | $340.1M | ||
| Q2 25 | $18.4M | $224.7M | ||
| Q1 25 | $8.3M | $99.0M | ||
| Q4 24 | $19.6M | $229.9M | ||
| Q3 24 | $17.3M | $103.8M | ||
| Q2 24 | $12.1M | $19.4M | ||
| Q1 24 | $20.6M | $8.0M |
总债务ASIXMD
| Q4 25 | — | $570.5M | ||
| Q3 25 | — | $577.2M | ||
| Q2 25 | — | $583.9M | ||
| Q1 25 | — | $590.5M | ||
| Q4 24 | — | $597.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASIXMD
| Q4 25 | $815.2M | $865.9M | ||
| Q3 25 | $818.2M | $890.7M | ||
| Q2 25 | $823.7M | $833.8M | ||
| Q1 25 | $794.4M | $789.2M | ||
| Q4 24 | $774.6M | $764.9M | ||
| Q3 24 | $766.4M | $732.5M | ||
| Q2 24 | $746.6M | $706.5M | ||
| Q1 24 | $713.2M | $856.2M |
总资产ASIXMD
| Q4 25 | $1.7B | $2.2B | ||
| Q3 25 | $1.7B | $2.2B | ||
| Q2 25 | $1.6B | $2.1B | ||
| Q1 25 | $1.6B | $2.0B | ||
| Q4 24 | $1.6B | $2.2B | ||
| Q3 24 | $1.5B | $2.1B | ||
| Q2 24 | $1.5B | $2.0B | ||
| Q1 24 | $1.5B | $2.2B |
负债/权益比ASIXMD
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $114.1M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | — |
| 自由现金流率自由现金流/营收 | 10.0% | — |
| 资本支出强度资本支出/营收 | 7.7% | — |
| 现金转化率经营现金流/净利润 | — | 3.39× |
| 过去12个月自由现金流最近4个季度 | $6.4M | — |
8季度趋势，按日历期对齐
经营现金流ASIXMD
| Q4 25 | $63.7M | $114.1M | ||
| Q3 25 | $26.6M | $137.3M | ||
| Q2 25 | $21.1M | $137.2M | ||
| Q1 25 | $11.4M | $-117.5M | ||
| Q4 24 | $64.2M | $133.0M | ||
| Q3 24 | $57.3M | $91.8M | ||
| Q2 24 | $50.2M | $107.0M | ||
| Q1 24 | $-36.2M | $-125.2M |
自由现金流ASIXMD
| Q4 25 | $36.1M | — | ||
| Q3 25 | $66.0K | — | ||
| Q2 25 | $-7.2M | — | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | — | ||
| Q2 24 | $16.7M | — | ||
| Q1 24 | $-71.6M | — |
自由现金流率ASIXMD
| Q4 25 | 10.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | -1.7% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -21.3% | — |
资本支出强度ASIXMD
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 7.4% | — | ||
| Q1 24 | 10.5% | — |
现金转化率ASIXMD
| Q4 25 | — | 3.39× | ||
| Q3 25 | — | 1.91× | ||
| Q2 25 | 0.67× | 3.49× | ||
| Q1 25 | 0.49× | -5.66× | ||
| Q4 24 | 182.29× | 4.36× | ||
| Q3 24 | 2.57× | 4.72× | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | -31.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
